VIVOS INC (RDGL)
RDGL moved a median of 0.00% 30 minutes after news, and +0.25% by the close. How RDGL actually reacts to news — the realized, point-in-time move the market made, measured across 88 labeled events over the last three years with zero look-ahead.
RDGL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 41% | 70 |
| 30-min | 0.00% | 43% | 86 |
| 60-min | 0.00% | 41% | 87 |
| to close | +0.25% | 51% | 87 |
| Middle 50% of RDGL reactions | -2.06% to +2.16% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 88 |
Half of all VIVOS INC news events land between -2.06% and +2.16% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when RDGL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RDGL's baseline. Nothing else.
Recent RDGL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K VIVOS INC For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | -6.18% | +3.54% | |
| Form 8-K VIVOS INC For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | -1.16% | +5.26% | |
| Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology | Press release | GlobeNewswire | -0.57% | -4.46% | |
| Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet® Shipments from New U.S. Production Facility and Authorization from India’s Nuclear Regulatory Authority for International Manufacturing Center | Press release | GlobeNewswire | +0.00% | -2.94% | |
| Form 10-Q VIVOS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.89% | +4.33% | |
| Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update | Press release | GlobeNewswire | +0.17% | +0.25% | |
| Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - Correction | Press release | GlobeNewswire | — | -3.04% | |
| Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™ | Press release | GlobeNewswire | +23.08% | +32.00% | |
| Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing | Press release | GlobeNewswire | +0.00% | +3.73% | |
| Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™ | Press release | GlobeNewswire | +3.45% | -4.70% | |
| Form 10-Q VIVOS INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.35% | |
| Form 10-K VIVOS INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.75% | +1.21% | |
| Form QUALIF VIVOS INC | SEC filing · Form QUALIF | SEC EDGAR | -0.13% | -1.09% | |
| Form 1-A/A VIVOS INC | SEC filing · Form 1-A | SEC EDGAR | +3.63% | -0.63% | |
| Form 1-A VIVOS INC | SEC filing · Form 1-A | SEC EDGAR | +0.00% | -2.97% | |
| Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites | Press release | GlobeNewswire | +0.00% | -2.97% | |
| Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ | Press release | GlobeNewswire | -1.70% | +4.20% | |
| Vivos Inc Updates Human Therapy Progress in India | Press release | GlobeNewswire | +3.70% | +3.41% | |
| Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals | Press release | GlobeNewswire | -5.61% | -6.37% | |
| Vivos Inc Summarizes Progress in its Animal Therapy Division | Press release | GlobeNewswire | — | -1.44% | |
| Vivos Inc Summarzes Preogress in its Animal Therapy Division | Press release | GlobeNewswire | +0.00% | +1.94% | |
| Form 10-Q VIVOS INC For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.04% | |
| Vivos Inc. Issues Shareholder Update Letter | Press release | GlobeNewswire | +8.00% | +3.00% | |
| Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics | Press release | GlobeNewswire | +1.07% | +1.59% | |
| Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel® | Press release | GlobeNewswire | +2.38% | +4.62% | |
| Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India | Press release | GlobeNewswire | +0.00% | +1.00% | |
| Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India | Press release | GlobeNewswire | — | -0.16% | |
| Form 8-K/A VIVOS INC For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -1.90% | -4.94% | |
| Form 8-K VIVOS INC For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.41% | |
| Form 8-K VIVOS INC For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.83% | |
| Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy | Press release | GlobeNewswire | +5.15% | +5.68% | |
| Vivos Inc Files Critical Patent For Hydrogel Electron Beam Sterilization | Press release | GlobeNewswire | +1.22% | +0.47% | |
| Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDA | Press release | GlobeNewswire | +14.00% | +70.00% | |
| Form 10-Q VIVOS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.48% | -0.48% | |
| Vivos Inc. Submitted the Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Clinic | Press release | GlobeNewswire | +16.54% | +8.42% | |
| Vivos Inc. Certifies University of Florida Veterinary Hospital for IsoPet® Precision Radionuclide Therapy™ | Press release | GlobeNewswire | +0.00% | -0.54% | |
| Form 10-Q VIVOS INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.59% | -3.84% | |
| Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025 | Press release | GlobeNewswire | -2.86% | +0.00% | |
| Vivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuclide Therapy™ | Press release | GlobeNewswire | +6.52% | +12.95% | |
| Form 10-K VIVOS INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | +1.74% | |
| Form 8-K VIVOS INC For: Feb 04 | SEC filing · Form 8-K | SEC EDGAR | +0.69% | +1.09% | |
| Form 8-K VIVOS INC For: Feb 06 | SEC filing · Form 8-K | SEC EDGAR | — | +1.39% | |
| Vivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans | Press release | GlobeNewswire | +3.04% | -3.79% | |
| Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide | Press release | GlobeNewswire | -2.08% | -7.69% | |
| Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical Trial | Press release | GlobeNewswire | +7.46% | +3.34% | |
| Form 253G2 VIVOS INC | SEC filing · Form 253G2 | SEC EDGAR | +0.00% | +0.99% | |
| Form 10-Q VIVOS INC For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | — | +0.00% | |
| Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM | Press release | GlobeNewswire | +0.00% | +0.65% | |
| Vivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM to Exotics | Press release | GlobeNewswire | +0.99% | +4.87% | |
| Form 10-Q VIVOS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | +1.90% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RDGL section they belong to.
Where else RDGL is measured.
RDGL earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Acasti Pharma, Inc. (ACST) | 89 | 0.00% | 44% |
| Microbix Biosystems Inc (MBX_TSE) | 89 | 0.00% | 32% |
| AMBU A S UNSP/ADR (AMBBY) | 87 | 0.00% | 13% |
| INTERPACE BIOSCIENCES INC (IDXG) | 87 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is VIVOS INC's median reaction calculated?
Every labeled RDGL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 88 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of RDGL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RDGL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.